射频诱导热化疗对比二次卡介苗或机构标准治疗BCG失败NMIBC的III期随机试验(HYMN)
HYMN是一项开放标签III期随机对照试验,纳入104例 induction/维持BCG治疗后复发的NMIBC患者,比较RITE与机构标准二线治疗的DFS。结果显示两组DFS无显著差异(HR 1.33,95%CI 0.84-2.10,p=0.23),CIS患者3个月CR率也无显著差异(RITE 30% vs 对照47%,p=0.15)。CIS±乳头状患者中RITE组DFS显著更低(HR 2.06,95%CI 1.17-3.62,p=0.01)。
要点
- BCG失败后RITE与标准二线治疗DFS无显著差异。
- CIS±乳头状患者中RITE组DFS显著低于对照。
- 非CIS患者两组DFS无显著差异,RITE可能为候选。
核心结论
- RITE与对照二线治疗的DFS相似,但CIS±乳头状患者中RITE组DFS显著更低。
- RITE可能作为BCG失败后非CIS复发的二线治疗,但需确证性试验。
研究设计与样本
- 开放标签III期随机对照试验,2010年5月至2013年7月从14个中心入组104例BCG诱导/维持治疗后复发的NMIBC患者。
- 患者按1:1随机分配至RITE(60分钟,40mg丝裂霉素-C,42±2°C)或机构标准二线治疗,按CIS状态、治疗史和中心分层。
- 主要终点为DFS和CIS亚组随机化时3个月完全缓解率,采用意向性治疗分析。
主要发现
- 两组DFS无显著差异(HR 1.33,95%CI 0.84-2.10,p=0.23)。
- CIS患者3个月CR率无显著差异(n=71;RITE 30% vs 对照47%,p=0.15)。
- 非CIS患者两组DFS无显著差异(n=33;24个月RITE 53% vs 对照24%,HR 0.50,95%CI 0.22-1.17,p=0.11)。
- CIS±乳头状患者中RITE组DFS显著低于对照(n=71;HR 2.06,95%CI 1.17-3.62,p=0.01;治疗-亚组交互p=0.007)。
- 两组疾病进展各4例,不良事件和健康相关生活质量相当。
关键数值与推荐
- RITE方案:60分钟,40mg丝裂霉素-C,42±2°C。
- DFS无显著差异的HR为1.33(95%CI 0.84-2.10,p=0.23)。
- CIS患者3个月CR率RITE 30% vs 对照47%(p=0.15)。
- CIS±乳头状患者DFS的HR为2.06(95%CI 1.17-3.62,p=0.01)。
临床怎么用
- BCG失败后RITE不宜常规用于CIS±乳头状患者,因其DFS显著低于对照。
- 非CIS复发患者可考虑RITE作为二线选择,但需更多确证性研究。
- RITE与标准治疗耐受性相当,不良事件和健康相关生活质量无显著差异。
局限性
- 样本量较小(共104例),部分亚组分析例数有限。
- 随访时间有限,31例无DFS事件患者中位随访36个月。
- 开放标签设计可能引入偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is no effective intravesical second-line therapy for non-muscle-invasive bladder cancer (NMIBC) when bacillus Calmette-Guérin (BCG) fails. OBJECTIVE: To compare disease-free survival time (DFS) between radiofrequency-induced thermo-chemotherapy effect (RITE) and institutional standard second-line therapy (control) in NMIBC patients with recurrence following induction/maintenance BCG. DESIGN, SETTINGS, AND PARTICIPANTS: Open-label, phase III randomised controlled trial accrued across 14 centres between May 2010 and July 2013 (HYMN [ClinicalTrials.gov: NCT01094964]). INTERVENTION: Patients were randomly assigned (1:1) to RITE (60min, 40mg mitomycin-C, 42±2°C) or control following stratification for carcinoma in situ (CIS) status (present/absent), therapy history (failure of previous induction/maintenance BCG), and treatment centre. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary outcome measures were DFS and complete response (CR) at 3 mo for the CIS at randomisation subgroup. Analysis was based on intention-to-treat. RESULTS AND LIMITATIONS: A total of 104 patients were randomised (48 RITE: 56 control). Median follow-up for the 31 patients without a DFS event was 36 mo. There was no significant difference in DFS between treatment arms (hazard ratio [HR] 1.33, 95% confidence interval [CI] 0.84-2.10, p=0.23) or in 3-mo CR rate in CIS patients (n=71; RITE: 30% vs control: 47%, p=0.15). There was no significant difference in DFS between treatment arms in non-CIS patients (n=33; RITE: 53% vs control: 24% at 24 mo, HR 0.50, 95% CI 0.22-1.17, p=0.11). DFS was significantly lower in RITE than in control in CIS with/without papillary patients (n=71; HR 2.06, 95% CI 1.17-3.62, p=0.01; treatment-subgroup interaction p=0.007). Disease progression was observed in four patients in each treatment arm. Adverse events and health-related quality of life between treatment arms were comparable. CONCLUSIONS: DFS was similar between RITE and control. RITE may be a second-line therapy for non-CIS recurrence following BCG failure; however, confirmatory trials are needed. RITE patients with CIS with/without papillary had lower DFS than control. HYMN highlights the importance of the control arm when evaluating novel therapies. PATIENT SUMMARY: This study did not show a difference in bladder cancer outcomes between microwave-heated chemotherapy and standard of care treatment. Papillary bladder lesions may benefit from microwave-heated chemotherapy treatment; however, more research is needed. Both treatments are similarly well tolerated.
引用
- Tan WS, Panchal A, Buckley L, et al. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. Eur Urol. 2018. PMID: 30274699. doi:10.1016/j.eururo.2018.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。